Login  |  Register

Lilly and AstraZeneca's AZD3293 Fast Track'd for early ...

The FDA designates Phase 3-stage AZD3293 for Fast Track review for the treatment of early Alzheimer's disease ((AD)). AZD3293 inhibits an enzyme called BAC

Alexa Traffic